patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_687715 | REC_0003701 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.2 | 66 | female | 1 | 17 | 3.6 | 2 | entrectinib 600 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:57.759739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422858 | REC_0003702 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.8 | 60 | female | 1 | 17 | 5.2 | 6 | alectinib 600 mg BID | 12 | false | MSI-H | 2026-03-15T05:35:57.759985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883068 | REC_0003703 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.2 | 57 | female | 0 | 10 | 4.4 | 6 | entrectinib 600 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:57.760358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237071 | REC_0003704 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.3 | 76 | male | 2 | 50 | 4.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:57.760662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893602 | REC_0003705 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.1 | 66 | female | 0 | 46 | 6.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:57.760929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832363 | REC_0003706 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.8 | 76 | female | 1 | 12 | 3.4 | 4 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.761310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207285 | REC_0003707 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 6.6 | 57 | male | 1 | 22 | 6.8 | 2 | sotorasib 960 mg daily | 19.6 | false | MSS | 2026-03-15T05:35:57.761559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909339 | REC_0003708 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.7 | 67 | female | 0 | 27 | 4.6 | 2 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:35:57.761792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275855 | REC_0003709 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 6.5 | 61 | female | 1 | 15 | 5.2 | 4 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.762032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766883 | REC_0003710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 16 | 61 | female | 1 | 3 | 3.6 | 2 | osimertinib 80 mg daily | 15.9 | true | MSI-H | 2026-03-15T05:35:57.762270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334148 | REC_0003711 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 1.5 | 88 | female | 2 | 20 | 4.5 | 5 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:57.762505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670163 | REC_0003712 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.8 | 66 | female | 1 | 57 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.7 | true | MSS | 2026-03-15T05:35:57.762738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584918 | REC_0003713 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.6 | 57 | male | 0 | 15 | 4.3 | 3 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.762975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711242 | REC_0003714 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 16.2 | 61 | female | 0 | 4 | 6 | 5 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.763214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182512 | REC_0003715 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.3 | 69 | female | 0 | 50 | 8.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:57.763445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669453 | REC_0003716 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.2 | 72 | female | 2 | 56 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:57.763675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200389 | REC_0003717 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 14 | 66 | male | 1 | 27 | 6.2 | 6 | sotorasib 960 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:57.763911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849968 | REC_0003718 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 12 | 71 | female | 1 | 13 | 5.5 | 2 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.764220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629487 | REC_0003719 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.6 | 82 | female | 1 | 49 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | true | MSS | 2026-03-15T05:35:57.764532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103724 | REC_0003720 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 13.4 | 73 | male | 2 | 13 | 6.6 | 2 | alectinib 600 mg BID | 12.6 | false | MSI-H | 2026-03-15T05:35:57.764782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189685 | REC_0003721 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.5 | 62 | female | 0 | 48 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:57.765018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309929 | REC_0003722 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 15.7 | 73 | female | 1 | 25 | 5.8 | 0 | osimertinib 80 mg daily | 44.6 | false | MSI-H | 2026-03-15T05:35:57.765256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773518 | REC_0003723 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.3 | 63 | male | 1 | 42 | 3.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:57.765491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382207 | REC_0003724 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.2 | 72 | female | 1 | 21 | 7.1 | 6 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:35:57.765728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638154 | REC_0003725 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10 | 68 | male | 1 | 7 | 5.6 | 2 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:57.765965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936059 | REC_0003726 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.7 | 63 | male | 0 | 10 | 5.4 | 5 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.766198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856970 | REC_0003727 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 15.6 | 69 | female | 1 | 18 | 5.5 | 1 | osimertinib 80 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:35:57.766435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753309 | REC_0003728 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.2 | 70 | female | 2 | 18 | 5.8 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.766662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467410 | REC_0003729 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 14.8 | 65 | female | 0 | 8 | 6 | 4 | pembrolizumab 200 mg q3w | 16.4 | false | MSI-H | 2026-03-15T05:35:57.766896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303705 | REC_0003730 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.8 | 57 | female | 0 | 14 | 4.2 | 2 | sotorasib 960 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:57.767128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699654 | REC_0003731 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.4 | 67 | female | 1 | 10 | 5.7 | 1 | sotorasib 960 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:57.767358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961160 | REC_0003732 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 5.9 | 57 | female | 1 | 23 | 6.7 | 1 | sotorasib 960 mg daily | 26 | true | MSS | 2026-03-15T05:35:57.767636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583091 | REC_0003733 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 16.1 | 63 | female | 0 | 7 | 7.2 | 1 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:57.767874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117921 | REC_0003734 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 9.6 | 62 | female | 1 | 19 | 8.4 | 2 | alectinib 600 mg BID | 19.8 | false | MSS | 2026-03-15T05:35:57.768142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251108 | REC_0003735 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.2 | 50 | male | 0 | 7 | 4 | 1 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:57.768387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711634 | REC_0003736 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 10.1 | 58 | male | 0 | 8 | 3.9 | 5 | osimertinib 80 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:57.768629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134126 | REC_0003737 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.2 | 72 | female | 1 | 28 | 6.1 | 2 | osimertinib 80 mg daily | 32 | false | MSI-H | 2026-03-15T05:35:57.768869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796080 | REC_0003738 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.6 | 71 | female | 1 | 14 | 4.2 | 0 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:35:57.769100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608466 | REC_0003739 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.2 | 57 | male | 0 | 54 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:35:57.769339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544325 | REC_0003740 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.7 | 72 | female | 3 | 31 | 6.4 | 8 | pembrolizumab 200 mg q3w | 8.1 | false | MSS | 2026-03-15T05:35:57.769571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488122 | REC_0003741 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 17.3 | 67 | female | 1 | 16 | 7.3 | 2 | osimertinib 80 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:35:57.769804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166730 | REC_0003742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 2.3 | 73 | female | 0 | 19 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:57.770033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835523 | REC_0003743 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.3 | 69 | female | 0 | 22 | 5.3 | 5 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.770264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827099 | REC_0003744 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.2 | 63 | female | 1 | 19 | 5 | 5 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:57.770497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207181 | REC_0003745 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 11.8 | 57 | male | 0 | 20 | 3.8 | 1 | sotorasib 960 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:57.770800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549916 | REC_0003746 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.6 | 62 | male | 1 | 40 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.2 | false | MSS | 2026-03-15T05:35:57.771036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421514 | REC_0003747 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 12.7 | 58 | female | 1 | 14 | 4.2 | 2 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:57.771274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503247 | REC_0003748 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.7 | 64 | male | 0 | 18 | 4.7 | 7 | pembrolizumab 200 mg q3w | 10.2 | false | MSS | 2026-03-15T05:35:57.771506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514531 | REC_0003749 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.5 | 86 | female | 0 | 9 | 6.7 | 7 | sotorasib 960 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:57.771740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907778 | REC_0003750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.9 | 63 | male | 1 | 11 | 4.8 | 7 | entrectinib 600 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.771976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647282 | REC_0003751 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 3.2 | 73 | female | 1 | 7 | 4 | 2 | pembrolizumab 200 mg q3w | 16.9 | true | MSS | 2026-03-15T05:35:57.772257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171475 | REC_0003752 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 6.6 | 59 | female | 0 | 6 | 7.4 | 2 | osimertinib 80 mg daily | 26 | false | MSS | 2026-03-15T05:35:57.772506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574419 | REC_0003753 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.4 | 75 | male | 2 | 80 | 4.7 | 1 | pembrolizumab 200 mg q3w | 22.7 | true | MSS | 2026-03-15T05:35:57.772744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652207 | REC_0003754 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 14.4 | 69 | male | 0 | 7 | 5.1 | 2 | alectinib 600 mg BID | 20.2 | false | MSI-H | 2026-03-15T05:35:57.772982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376467 | REC_0003755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 7 | 78 | female | 2 | 49 | 4.8 | 5 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:57.773211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743402 | REC_0003756 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 10 | 60 | female | 1 | 20 | 6.7 | 0 | osimertinib 80 mg daily | 45.4 | true | MSS | 2026-03-15T05:35:57.773449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294955 | REC_0003757 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.5 | 64 | female | 1 | 18 | 3.2 | 6 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:57.773684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802085 | REC_0003758 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 10.3 | 55 | male | 0 | 17 | 3.8 | 5 | pembrolizumab 200 mg q3w | 4.9 | true | MSS | 2026-03-15T05:35:57.773980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783923 | REC_0003759 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 3.6 | 74 | female | 2 | 4 | 5.2 | 0 | osimertinib 80 mg daily | 37.6 | true | MSS | 2026-03-15T05:35:57.774213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874660 | REC_0003760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 13.4 | 75 | male | 1 | 18 | 4.8 | 4 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.774448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864120 | REC_0003761 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.3 | 71 | female | 2 | 10 | 4.6 | 5 | entrectinib 600 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:35:57.774681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176576 | REC_0003762 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.3 | 82 | female | 1 | 11 | 5.4 | 2 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.774913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480692 | REC_0003763 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.8 | 70 | female | 0 | 18 | 4.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:57.775145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726400 | REC_0003764 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.2 | 71 | female | 1 | 25 | 3.6 | 4 | alectinib 600 mg BID | 13.6 | true | MSS | 2026-03-15T05:35:57.775376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999970 | REC_0003765 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 10.4 | 50 | male | 0 | 26 | 4.2 | 0 | osimertinib 80 mg daily | 21.7 | true | MSS | 2026-03-15T05:35:57.775611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648694 | REC_0003766 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 7.9 | 70 | female | 1 | 23 | 4.9 | 2 | osimertinib 80 mg daily | 26.1 | false | MSS | 2026-03-15T05:35:57.775840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472708 | REC_0003767 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.9 | 71 | male | 1 | 0 | 4.8 | 5 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.776167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788918 | REC_0003768 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.4 | 57 | female | 0 | 19 | 2.9 | 2 | osimertinib 80 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:35:57.776435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622944 | REC_0003769 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 4 | 57 | female | 1 | 24 | 6.5 | 2 | alectinib 600 mg BID | 19.5 | false | MSS | 2026-03-15T05:35:57.776719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101734 | REC_0003770 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.2 | 60 | male | 0 | 54 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:57.776988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818170 | REC_0003771 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.4 | 62 | male | 1 | 14 | 4.9 | 6 | alectinib 600 mg BID | 9.9 | false | MSS | 2026-03-15T05:35:57.777426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188367 | REC_0003772 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5 | 75 | female | 1 | 41 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.9 | false | MSS | 2026-03-15T05:35:57.777720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885233 | REC_0003773 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.9 | 62 | female | 1 | 14 | 7.2 | 1 | sotorasib 960 mg daily | 31.7 | false | MSS | 2026-03-15T05:35:57.777986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606174 | REC_0003774 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.7 | 85 | female | 1 | 24 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:57.778258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631546 | REC_0003775 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 19.1 | 55 | male | 0 | 16 | 2.8 | 5 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:57.778512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554092 | REC_0003776 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.6 | 76 | male | 2 | 2 | 5.2 | 5 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:57.778748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354734 | REC_0003777 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 8.2 | 84 | female | 1 | 36 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:57.778986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488939 | REC_0003778 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.8 | 74 | female | 3 | 21 | 3.1 | 2 | alectinib 600 mg BID | 24.4 | true | MSI-H | 2026-03-15T05:35:57.779228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472603 | REC_0003779 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.6 | 61 | female | 0 | 6 | 5.4 | 6 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:57.779473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417063 | REC_0003780 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 8.4 | 66 | female | 0 | 17 | 7.3 | 1 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:57.779717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392142 | REC_0003781 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.7 | 65 | male | 0 | 18 | 5 | 6 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.779960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150072 | REC_0003782 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 6.5 | 57 | male | 0 | 11 | 6 | 2 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:35:57.780268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855275 | REC_0003783 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 6.4 | 71 | female | 2 | 16 | 7.2 | 0 | entrectinib 600 mg daily | 21.9 | true | MSS | 2026-03-15T05:35:57.780525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786540 | REC_0003784 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.8 | 73 | female | 1 | 12 | 5.3 | 4 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.780921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277353 | REC_0003785 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 4.2 | 60 | female | 0 | 3 | 5.1 | 3 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.781200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728962 | REC_0003786 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.6 | 67 | female | 0 | 14 | 4.9 | 2 | alectinib 600 mg BID | 15.4 | false | MSS | 2026-03-15T05:35:57.781446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583706 | REC_0003787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 7 | 61 | female | 0 | 2 | 3.5 | 6 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.781686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444611 | REC_0003788 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.2 | 61 | male | 1 | 54 | 4.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:57.781927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449533 | REC_0003789 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.6 | 70 | male | 1 | 12 | 4.3 | 5 | alectinib 600 mg BID | 5.4 | false | MSS | 2026-03-15T05:35:57.782168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798118 | REC_0003790 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 7.4 | 73 | male | 2 | 14 | 4.3 | 7 | pembrolizumab 200 mg q3w | 7.1 | true | MSS | 2026-03-15T05:35:57.782400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454453 | REC_0003791 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 1.5 | 57 | male | 1 | 7 | 4.9 | 5 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:57.782635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351635 | REC_0003792 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 36 | 16 | 65 | female | 1 | 18 | 6 | 7 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:35:57.782872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877516 | REC_0003793 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 11.8 | 63 | female | 1 | 20 | 5.3 | 2 | entrectinib 600 mg daily | 20.4 | false | MSI-H | 2026-03-15T05:35:57.783109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677008 | REC_0003794 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.7 | 75 | female | 2 | 21 | 5.2 | 4 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:57.783336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370370 | REC_0003795 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.9 | 79 | male | 2 | 9 | 5.7 | 1 | entrectinib 600 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:57.783576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816471 | REC_0003796 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 1.8 | 73 | female | 2 | 11 | 5.1 | 5 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.783804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393053 | REC_0003797 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 17.5 | 64 | female | 1 | 21 | 5.9 | 0 | alectinib 600 mg BID | 20.4 | true | MSS | 2026-03-15T05:35:57.784266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384236 | REC_0003798 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.3 | 61 | male | 0 | 32 | 5.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 17.5 | true | MSS | 2026-03-15T05:35:57.784531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297159 | REC_0003799 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 68 | male | 0 | 59 | 4 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:57.784785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222112 | REC_0003800 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.9 | 60 | male | 0 | 32 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:57.785030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.